psoriatic arthritis
Rheumatology · 2006–2026
51decisions
16medicines
21carried consumer input
26individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| ustekinumab Treatment of adult patients with severe chronic plaque psoriasis and severe psoriatic arthritis. | Mar 2026 | Recommended | no section in document |
| etanercept Severe psoriatic arthritis, ankylosing spondylitis, severe active rheumatoid arthritis, severe chronic plaque psoriasis, and severe active juvenile idiopathic… | Jul 2025 | Recommended with restriction | none received |
| infliximab Multiple indications including rheumatoid arthritis, psoriatic arthritis, Crohn's disease in adults and children (6 to 17 years), refractory Crohn's disease,… | Jul 2025 | Recommended with restriction | input received Colitis Australia |
| infliximab Biosimilar to Remicade for rheumatoid arthritis, psoriatic arthritis, Crohn's disease (adults and children 6-17 years), refractory Crohn's disease, ankylosing… | Mar 2025 | Recommended with restriction | input received |
| infliximab Amendment to restriction level for continuing treatment of severe active rheumatoid arthritis, severe Crohn disease, severe chronic plaque psoriasis, severe… | Mar 2025 | Recommended with restriction | input received |
| ustekinumab Severe chronic plaque psoriasis, severe psoriatic arthritis, severe Crohn disease, complex refractory fistulising Crohn disease, and moderate to severe… | Mar 2025 | Recommended with restriction | input received |
| bimekizumab Treatment of severe active psoriatic arthritis (PsA) in adult patients without an adequate response to conventional disease modifying anti-rheumatic drugs… | Mar 2024 | Recommended with restriction | input received CreakyJoints Australia |
| tofacitinib Severe active rheumatoid arthritis (initial treatment, first continuing treatment, and subsequent continuing treatment) and severe psoriatic arthritis (initial… | Mar 2024 | Recommended with restriction | input received CreakyJoints Australia · Global Healthy Living Foundation Australia |
| ustekinumab Treatment of paediatric severe chronic plaque psoriasis, severe Crohn disease, moderate to severe ulcerative colitis, and complex refractory fistulising Crohn… | Mar 2024 | Recommended | input received Colitis Australia |
| ustekinumab Severe chronic plaque psoriasis (adult and paediatric), severe psoriatic arthritis, severe Crohn disease, and complex refractory fistulising Crohn disease. | Nov 2024 | Recommended | input received Colitis Australia |
| apremilast Severe active psoriatic arthritis in patients who have failed conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and are ineligible for,… | Mar 2023 | Not recommended | input received Musculoskeletal Australia · Australian Rheumatology Association |
| infliximab Treatment of ankylosing spondylitis, severe chronic plaque psoriasis, severe active psoriatic arthritis, and complex refractory fistulising Crohn's disease via… | Mar 2022 | Recommended with restriction | unclear |
| risankizumab Treatment of severe psoriatic arthritis in patients with inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs). | Mar 2022 | Recommended with restriction | input received Creaky Joints Australia |
| adalimumab Rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, hidradenitis suppurativa, chronic plaque psoriasis, ulcerative colitis, Crohn's disease, and… | Nov 2022 | Not recommended | 1 individuals |
| etanercept Listing of etanercept injection 50 mg in 1 mL single use dose-dispenser cartridges for the same indications as currently listed etanercept pre-filled syringes:… | Jul 2021 | Recommended with restriction | unclear |
| upadacitinib Severe active psoriatic arthritis in patients who have failed to achieve an adequate response to conventional disease modifying anti-rheumatic drugs (cDMARDs). | Mar 2021 | Recommended with restriction | none received |
| etanercept Severe active rheumatoid arthritis, severe psoriatic arthritis, ankylosing spondylitis, severe chronic plaque psoriasis, and juvenile idiopathic arthritis. | Nov 2021 | Recommended | unclear |
| etanercept Support for uptake of etanercept biosimilar (Brenzys) in patients with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and chronic plaque… | Dec 2020 | Not recommended | no section in document |
| guselkumab Severe psoriatic arthritis in adult patients who have failed to respond to methotrexate, sulfasalazine, or leflunomide. | Nov 2020 | Recommended with restriction | 1 individuals Creaky Joints Australia |
| infliximab Treatment of adults with severe active rheumatoid arthritis, ankylosing spondylitis, severe refractory Crohn's disease, complex refractory fistulising Crohn's… | Nov 2020 | Recommended with restriction | input received Colitis Australia · Parallel- Group |
| infliximab Subsequent continuing treatment for severe Crohn disease, complex refractory fistulising Crohn disease, moderate to severe Crohn disease, moderate to severe… | Mar 2019 | Recommended with restriction | 3 individuals |
| adalimumab Severe active rheumatoid arthritis, severe psoriatic arthritis, ankylosing spondylitis, severe chronic plaque psoriasis, juvenile idiopathic arthritis, severe… | Jul 2018 | Recommended | 1 individuals |
| ixekizumab Treatment of severe active psoriatic arthritis in adults who have responded inadequately or are intolerant to previous DMARD therapy. | Jul 2018 | Recommended with restriction | 3 individuals |
| abatacept Treatment of severe active psoriatic arthritis (PsA) in adults who have failed to achieve an adequate response to conventional non-biologic disease-modifying… | Mar 2018 | Not recommended | 11 individuals CreakyJoints Australia · Psoriasis Australia |
| etanercept Biosimilar etanercept for multiple indications including severe active rheumatoid arthritis, severe psoriatic arthritis, ankylosing spondylitis, severe chronic… | Mar 2018 | Recommended with restriction | none received |
| etanercept Proposed changes to the listing of etanercept (Brenzys brand) to support biosimilar uptake, including changes to authority requirements and treatment cycle… | Nov 2018 | Deferred | none received |
| tofacitinib Severe active psoriatic arthritis in patients who have had an inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs). | Nov 2018 | Recommended with restriction | none received |
| etanercept severe active rheumatoid arthritis, ankylosing spondylitis, severe psoriatic arthritis, and severe chronic plaque psoriasis | Aug 2017 | Recommended with restriction | no section in document |
| certolizumab pegol Treatment of severe active rheumatoid arthritis, severe psoriatic arthritis, and active ankylosing spondylitis. | Mar 2017 | Recommended with restriction | none received |
| infliximab Change to initial and continuing treatment restrictions for the biosimilar brand of infliximab (Renflexis) for severe active rheumatoid arthritis, ankylosing… | Nov 2017 | Recommended with restriction | none received |
| etanercept Biosimilar to etanercept for all indications for which etanercept (Enbrel) is currently PBS-listed: rheumatoid arthritis, ankylosing spondylitis, psoriatic… | Jul 2016 | Recommended | input received |
| certolizumab pegol Loading dose administration (weeks 0, 2, and 4) for patients with ankylosing spondylitis, severe psoriatic arthritis, and severe active rheumatoid arthritis. | Mar 2016 | Recommended with restriction | no section in document |
| secukinumab Treatment of severe active psoriatic arthritis in patients who have failed to achieve an adequate response to conventional synthetic disease-modifying… | Mar 2016 | Recommended with restriction | none received |
| infliximab Biosimilar to Remicade for multiple indications including rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, ulcerative colitis, and… | Nov 2016 | Recommended | none received |
| infliximab Biosimilar to Remicade for rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, ulcerative colitis, and Crohn's disease. | Jul 2015 | Recommended with restriction | 2 individuals |
| ustekinumab Treatment of active psoriatic arthritis in adult patients (18 years and older) where response to previous non-biological DMARD therapy has been inadequate,… | Jul 2015 | Deferred | 4 individuals |
| apremilast Treatment of severe active psoriatic arthritis in patients who have previously received and failed to achieve an adequate response to one or more… | Mar 2015 | Not recommended | none received |
| ustekinumab Treatment of psoriatic arthritis (PsA) in patients with active disease. | Nov 2015 | Recommended with restriction | none received |
| apremilast Treatment of severe active psoriatic arthritis (PsA) in adult patients where conventional DMARDs (methotrexate and sulfasalazine or leflunomide) are… | Nov 2015 | Not recommended | input received |
| certolizumab pegol Treatment of psoriatic arthritis in adult patients where response to previous disease modifying anti-rheumatic drugs (DMARDs) is inadequate. | Nov 2014 | Recommended with restriction | none received |
| ustekinumab Treatment of psoriatic arthritis (PsA) as an Authority Required listing for patients who have failed therapy with standard DMARDs. | Nov 2014 | Not recommended | none received |
| golimumab treatment of adult patients with severe active psoriatic arthritis | Mar 2010 | Recommended with restriction | no section in document |
| golimumab Treatment of adult patients with severe active psoriatic arthritis. | Mar 2010 | Recommended with restriction | no section in document |
| etanercept For treatment of rheumatoid arthritis (RA) and psoriatic arthritis (PsA) in patients with ≥10 tender and swollen joints or ≥2 major affected joints, with… | Jul 2008 | Recommended | no section in document |
| etanercept Extension of PBS listing for rheumatoid arthritis (RA) and psoriatic arthritis (PsA) to include patients with ≥10 tender and swollen joints or ≥2 major… | Jul 2008 | Not recommended | no section in document |
| leflunomide Initial treatment of severe active psoriatic arthritis where other disease modifying anti-rheumatic drugs (including methotrexate) are ineffective and/or… | Mar 2007 | Recommended with restriction | no section in document |
| leflunomide Treatment of active psoriatic arthritis in patients for whom other disease modifying anti-rheumatic drugs (including methotrexate) are inappropriate and/or… | Mar 2007 | Recommended with restriction | no section in document |
| adalimumab treatment of severe, active psoriatic arthritis | Mar 2006 | Recommended with restriction | no section in document |
| infliximab treatment of severe, active psoriatic arthritis in patients who meet certain criteria | Mar 2006 | Recommended | no section in document |
| adalimumab Treatment of severe, active psoriatic arthritis in patients where the response to previous DMARDs has been inadequate. | Mar 2006 | Recommended with restriction | no section in document |
| infliximab Treatment of severe, active psoriatic arthritis in patients who meet certain criteria. | Mar 2006 | Recommended with restriction | no section in document |
Who spoke
Colitis Australia · CreakyJoints Australia · Creaky Joints Australia · Psoriasis Australia · Parallel- Group · Global Healthy Living Foundation Australia · Musculoskeletal Australia · Australian Rheumatology Association
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 21 of 41 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.